Drug Delivery Platform Innovator
With Multiple Mainstream Applications
Corporate Presentation
May 2024
Lexaria Bioscience Corp.
NASDAQ:LEXX | NASDAQ:LEXXW
www.lexariabioscience.com
Email: ir@lexariabioscience.com
Disclaimer
This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, research and development, alternative health projects or products, clinical trials, regulatory approvals, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward- looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Bioscience Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Bioscience Corp. from time to time with regulatory authorities available on SEDAR+ at http://www.sedarplus.ca/and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes.
No statement within has been evaluated by the Food and Drug Administration, and no product or service is yet commercially approved and intended to diagnose, treat, cure or prevent any disease.
2
NASDAQ:LEXX | NASDAQ:LEXXW
Table of Contents
- Lexaria's Drug Delivery Platform Technology
- DehydraTECH Pipeline and Market Investigations
- DehydraTECH for Diabetes and Weight Loss
- DehydraTECH for Hypertension
- Management, Directors and Advisors
- Financial Information
- Investment Highlights
NASDAQ:LEXX | NASDAQ:LEXXW | 33 |
Lexaria's Drug Delivery Platform Technology | 01 |
NASDAQ:LEXX | NASDAQ:LEXXW | 44 |
DehydraTECH - Lexaria's Drug Delivery Platform Technology
- Enhances the pharmacokinetic performance of Active
Pharmaceutical Ingredients ("APIs") into the bloodstream and into brain tissue, increasing bioavailability, improving speed of onset and increasing brain absorption; - Multiple ℞ applications in weight loss, diabetes, hypertension and others;
- Can be applied multiple oral/intraoral product formats such as tablets, capsules, oral suspensions, mouth-meltsand others, and also to topicals;
- Focused on commercialization through partnerships, licensing and internal development;
- Awarded 41 patents granted and many more pending around the world for use with a broad range of bioactive molecules.
2024 Catalysts:
GLP-1 (Diabetes/Weight Loss):
- April - Long Term Stability & Mode of Action Testing
- May - Human Pilot Study #2: GLP-1-H24-2
- May - Animal Study: WEIGHT-A24-1
- June - Human Pilot Study #3: GLP-1-H24-3
- July - Human Study: GLP-1-H24-4
Hypertension:
- FDA Investigational New Drug opening study HYPER- H23-1
5
NASDAQ:LEXX | NASDAQ:LEXXW
DehydraTECH Mechanism of Action
Dissolvable Orals
LCFAs are believed to block and shunt associated APIs away from bitter taste receptors for APIs that need flavor masking(1)
LCFAs influence permeability in the oral cavity(2) (i.e., sublingually and/or buccally)
Adjunct ingredients are added to enhance oral cavity permeability performance
Ingestible Solid Orals / Liquids
LCFAs influence gastric cholecystokinin production and motility(4)
Small intestine quickly absorbs LCFA- associated APIs into the bloodstream via the lymphatics bypassing first pass liver effect(5)
Adjunct ingredients added to enhance stomach or small intestine uptake depending on desired site of absorption
Enhanced brain absorption
Once absorbed systemically through dissolvable or solid oral form factors, LCFA-associated APIs are believed to enter brain preferentially through fatty acid transport proteins(3)
LCFA = Long Chain Fatty Acid
(1) Coupland & Hayes (2014). Pharm Res. Nov 31(11); 2921-2939(2)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321376/(3)https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2011.07245.x(4)https://www.gastrojournal.org/article/S0016-5085(99)70227-1/fulltext#back-bib2(5)Based on dynamic light scattering particle size evaluation studies conducted by Canada's National Research Council as announced July 16, 2020/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202979/pdf/nihms330214.pdf" .
6
NASDAQ:LEXX | NASDAQ:LEXXW
DehydraTECH - Patented Technology Potential Benefits
Patented drug delivery technology improves oral administration of Active Pharmaceutical Ingredients
Masks unwanted | Improves speed of | Increases | Increases brain | Reduces Drug |
taste (1) | onset | bioavailability | absorption | Administration Costs |
Eliminates the | Effects are felt in | Much more | Testing suggests | Higher ratio of |
need for sugar- | minutes(2) | effective at | up to 17x | drug delivery |
filled edibles | delivering drug into | improvement(4) | expected to lower | |
bloodstream(3) | overall drug costs |
Better Patient Experience
Improved Quality of Life
- Based on subjective clinical testing in 29 human volunteers with CBD, THC and nicotine formulations and hundreds of thousands of commercial product servings of CBD and THC formulations by Lexaria's licensing partners.
- Based on subjective clinical testing in 82 human volunteers with CBD, THC and nicotine formulations and hundreds of thousands of commercial product servings of CBD and THC formulations by Lexaria's licensing partners.
- Based on objective clinical testing in 13 human volunteers with CBD formulations, and in vivo animal testing in 316 rodents with CBD and nicotine formulations
(4)https://ir.lexariabioscience.com/news-events/press-releases/detail/128/lexaria-issues-successful-results-from-first-2021-study | 7 |
NASDAQ:LEXX | NASDAQ:LEXXW
DehydraTECH Pipeline and Market Investigations 02
NASDAQ:LEXX | NASDAQ:LEXXW | 88 |
Past Work / Expansion Potential Active 2024 Programs
DehydraTECH Pipeline
Therapeutic / | Potential | Status | ||||||||||||||||||||||||
Identification | Modality | Formulation -->Animal PK --> | in vitro / | --> Human POC --> Registered Trials | ||||||||||||||||||||||
Commercial Use | Indication(s) | Animal PD | ||||||||||||||||||||||||
DehydraTECH-CBD | Small Molecule | Cardiovascular | St. 1/2 Hypertension* | |||||||||||||||||||||||
DehydraTECH-GLP-1/GIP | Peptide | Metabolic | Diabetes / Weight | |||||||||||||||||||||||
Disorders | Loss Management | |||||||||||||||||||||||||
DehydraTECH-CBD | Small Molecule | Metabolic | Diabetes / Weight | |||||||||||||||||||||||
Disorders | Loss Management | |||||||||||||||||||||||||
DehydraTECH-Nicotine | Small Molecule | Nicotine | N/A | |||||||||||||||||||||||
Replacement | ||||||||||||||||||||||||||
DehydraTECH-CBD | Small Molecule | Neurology | Seizure Disorders | 2024 Objectives (red): | ||||||||||||||||||||||
- HYPER-H23-1 Phase Ib | ||||||||||||||||||||||||||
DehydraTECH-Antiviral | Small Molecule | Antiviral | HIV/Covid-19/etc. | IND Authorization and | ||||||||||||||||||||||
Execution** | ||||||||||||||||||||||||||
- Comprehensive series of | ||||||||||||||||||||||||||
DehydraTECH-PDE5 | Small Molecule | Cardiovascular | Erectile Dysfunction | animal and human acute | ||||||||||||||||||||||
and chronic dosing GLP-1 | ||||||||||||||||||||||||||
DehydraTECH-Estradiol | Small Molecule | Hormone Therapy | HRT and Menopause | PK/PD/POC studies | ||||||||||||||||||||||
PK = Pharmacokinetic
PD = Pharmacodynamic
POC = Proof of Concept CBD = Cannabidiol
CPG = Consumer Packaged Good product GIP = Glucose dependent insulinotropic
polypeptide
GLP-1 = Glucagon-Like Peptide 1 Agonists PDE5 = Phosphodiesterase 5
HIV = Human Immunodeficiency Virus
HRT = Hormone Replacement Therapy
*For the treatment of stage 1 or stage 2 hypertensive patients not adequately managed with existing treatments ** Pending Additional Funding
9
NASDAQ:LEXX | NASDAQ:LEXXW
Commercial Opportunities
-
Lexaria management and directors have extensive experience in building relationships with
"Fortune 500" companies - Actively developing lead product pipeline candidates in the areas of:
- GLP-1drugs/diabetes and weight loss
- Hypertension and potentially heart disease
- Lexaria is currently engaged with other companies, exploring partnerships and opportunities with their specific APIs of interest
- Lexaria out-licenses its technology in exchange for up-front fees, milestone payments and/or royalty payments
- Lexaria is generating revenues now through the manufacture of corporate customer specified DehydraTECH formulations
10
NASDAQ:LEXX | NASDAQ:LEXXW
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Lexaria Bioscience Corp. published this content on 06 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2024 20:01:06 UTC.